VELSIPITY's Patent Clock Ticks Longer: FDA's Daily Grind
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for VELSIPITY, a new drug, so its patent can be extended. This means the company behind VELSIPITY gets more time to protect their invention before others can copy it. If you’re involved in drug patents or development, this timing update could impact your plans and profits.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-11315, Determination of Regulatory Review Period for Purposes of Patent Extension; QALSODY
The FDA has officially set the review period for QALSODY, a human drug product, so its patent can be extended. This helps the company behind QALSODY get extra time to protect their invention before generics can enter the market. If you’re in the drug business or follow patents, this means a bit more time before cheaper versions show up, potentially affecting prices and competition.
Next: 2025-11317, Determination of Regulatory Review Period for Purposes of Patent Extension; ALTUVIIIO
The FDA has officially set the review period for ALTUVIIIO, a human biological product, so its patent can be extended. This means the company behind ALTUVIIIO gets more time to protect their invention and keep competitors at bay. If you’re in the business of making or selling similar products, this update could affect when new versions hit the market and how long the original patent lasts.